Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Non Operating Income (2018 - 2025)

Bioadaptives' Non Operating Income history spans 7 years, with the latest figure at -$575229.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 1569.8% to -$575229.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$515725.0, a 73.6% decrease, with the full-year FY2025 number at -$515725.0, down 73.6% from a year prior.
  • Non Operating Income hit -$575229.0 in Q4 2025 for Bioadaptives, down from -$113813.0 in the prior quarter.
  • Over the last five years, Non Operating Income for BDPT hit a ceiling of $138337.0 in Q3 2021 and a floor of -$575229.0 in Q4 2025.
  • Historically, Non Operating Income has averaged -$109193.9 across 5 years, with a median of -$89003.5 in 2023.
  • Biggest five-year swings in Non Operating Income: surged 1135.48% in 2021 and later crashed 21081.23% in 2023.
  • Tracing BDPT's Non Operating Income over 5 years: stood at -$36549.0 in 2021, then skyrocketed by 97.33% to -$975.0 in 2022, then crashed by 21081.23% to -$206517.0 in 2023, then surged by 83.32% to -$34449.0 in 2024, then crashed by 1569.8% to -$575229.0 in 2025.
  • Business Quant data shows Non Operating Income for BDPT at -$575229.0 in Q4 2025, -$113813.0 in Q3 2025, and $121305.0 in Q2 2025.